This study presented targeted delivery of small interfering ribonucleic acids (siRNA) to suppress the expression of NET-1, found to be overexpressed in HCC cells, with an antibody to Glypican-3 (GPC3), that is expressed in HCC but not normal hepatocytes [86]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.